Evidence map›Paper›PMID 35835912›Full record

ArticleNature genetics2022

Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.

Siddhartha P Kar, Pedro M Quiros, Muxin Gu, Tao Jiang, Jonathan Mitchell, Ryan Langdon, Vivek Iyer, Clea Barcena, M S Vijayabaskar, Margarete A Fabre and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Nature genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 247 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
247citing papers in PubMed, 6 pooled it
50.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

247 citing papers in PubMed, 6 syntheses or guidelines pooled it, 333 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Biological effects of high-LET irradiation on the circulatory system.International journal of radiation biology · 2025
    Pooled it
  4. Pooled it
  5. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2024
    Pooled it
  6. Pooled it
  7. Trial
  8. Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Genetic mechanisms of mitotic error in 840,853 blood genomes.medRxiv : the preprint server for health sciences · 2026
    Article
  14. Article
  15. Exacerbation of inflammatory bone loss in TET2-driven clonal hematopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  16. Article
  17. Risk factors of clonal hematopoiesis of indeterminate potential.Clinical medicine (London, England) · 2026
    Article
  18. Article
  19. Review
  20. Article

187 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Siddhartha P Kar *MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. siddhartha.kar@bristol.ac.uk.ORCID http://orcid.org/0000-0002-2314-1426
Pedro M Quiros *Department of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK. pmquiros@ispasturias.es.ORCID http://orcid.org/0000-0002-7793-6291
Muxin GuDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Tao JiangBHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.
Jonathan MitchellCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Ryan LangdonMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Vivek IyerWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Clea BarcenaDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
M S VijayabaskarDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Margarete A FabreDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Paul CarterDivision of Cardiovascular Medicine, Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Slavé PetrovskiCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Stephen BurgessBHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5365-8760
George S VassiliouDepartment of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK. gsv20@cam.ac.uk.ORCID http://orcid.org/0000-0003-4337-8022
Wellcome/MRC Cambridge Stem Cell Institute · GBAstraZeneca (United Kingdom) · GBUniversity of Cambridge · GBAt Bristol · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity of Bristol · GBWellcome Sanger Institute · GB

Funding

British Heart Foundation CH/12/2/29428British Heart Foundation RG/13/13/30194British Heart Foundation RG/18/13/33946Cancer Research UK 23015Cancer Research UK 29019Cancer Research UK A23015Cancer Research UK A29019Cancer Research UK C18281/A29019Cancer Research UK C22324/A23015Department of Health BRC-1215-20014Medical Research Council MC_PC_17228Medical Research Council MC_PC_17230Medical Research Council MC_QA137853Medical Research Council MC_UU_00002/7Medical Research Council MR/T043202/1Wellcome Trust 098051Wellcome Trust 204623Wellcome Trust 204623/Z/16/ZWellcome Trust WT098051
6 · The paper itself

Abstract

Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations, affects over a third of people, yet remains poorly understood. Here we analyze genetic data from 200,453 UK Biobank participants to map the landscape of inherited predisposition to CH, increasing the number of germline associations with CH in European-ancestry populations from 4 to 14. Genes at new loci implicate DNA damage repair (PARP1, ATM, CHEK2), hematopoietic stem cell migration/homing (CD164) and myeloid oncogenesis (SETBP1). Several associations were CH-subtype-specific including variants at TCL1A and CD164 that had opposite associations with DNMT3A- versus TET2-mutant CH, the two most common CH subtypes, proposing key roles for these two loci in CH development. Mendelian randomization analyses showed that smoking and longer leukocyte telomere length are causal risk factors for CH and that genetic predisposition to CH increases risks of myeloproliferative neoplasia, nonhematological malignancies, atrial fibrillation and blood epigenetic ageing.

Indexed as

Clonal HematopoiesisHematopoiesisCell Transformation, NeoplasticGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMutationRisk Factors

Identifiers

PMID35835912
PMCPMC9355874
OpenAlexW4285387237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.